Atea Pharma Secures $50M Milestone Payment with Roche in the Development of AT-527 for COVID-19

 Atea Pharma Secures $50M Milestone Payment with Roche in the Development of AT-527 for COVID-19

Atea Pharma Secures $50M Milestone Payment with Roche in the Development of AT-527 for COVID 19

Shots:

  • Atea Pharma achieved a milestone related to the development of AT-527 and is expecting to receive a related payment of $50M under its license agreement with Roche. The company believes that AT-527 is suitable for use in both pre-and post-exposure prophylactic settings and complementary to vaccines
  • The companies are jointly developing AT-527 for the treatment of COVID-19 where Atea retains commercialization rights for AT-527 in the US and Roche holds the exclusive right to commercialize AT-527 outside of the US
  • AT-527 is currently being evaluated in the global P-III MORNINGSKY trial, P-II study for hospitalized patients with moderate COVID-19, and a P-II outpatient study in patients with mild or moderate COVID-19

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Bain Capital

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post